J B Chemicals and Pharmaceuticals Ltd
NSE:JBCHEPHARM
JBCHEPHARM's latest stock split occurred on Sep 18, 2023
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, JBCHEPHARM traded at 1478.47 per share. Afterward, the share price was about 1484.7.
The adjusted shares began trading on Sep 18, 2023. This was JBCHEPHARM's 4th stock split, following the previous one in Apr 5, 2005.
SNNAF
J B Chemicals and Pharmaceuticals Ltd
Glance View
In the bustling marketplace of India's pharmaceutical industry, J B Chemicals and Pharmaceuticals Ltd. has carved its niche, a testament to its strategic vision and operational prowess. Founded in 1976 by Janak Mehta, the company has grown from its humble beginnings into a leading player in both the domestic and international arenas. Originally rooted in the ethos of quality and innovation, it established a firm foothold in the pharmaceutical sector through a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and contract manufacturing. As a vertically integrated company, J B Chemicals leverages its ability to control the manufacturing process from start to finish, ensuring strict quality measures and cost efficiencies, vital in tackling industry competition and regulatory challenges. The heart of J B Chemicals’ revenue model is its well-rounded product line that spans a range of therapeutic categories, including gastrointestinal, cardiovascular, and anticold segments. Blockbuster brands like Cilacar and Metrogyl have propelled the company to the top ranks within India, while its export division flourishes, contributing significantly to total earnings. With footprints in more than 30 countries, particularly in Russia and South Africa, the company taps into the growing demand for generic medicines worldwide. Moreover, by embracing innovation and investing in research and development, J B Chemicals continues to introduce new and improved medical solutions, positioning itself as a dynamic player in meeting global healthcare needs.
You don't have any saved screeners yet